<DOC>
	<DOCNO>NCT01316042</DOCNO>
	<brief_summary>The primary objective study determine safety efficacy metformin lower serum DHEAS level girl premature pubarche secondary , observe change hormone associate pubertal development include gonadotropin , sex steroid , insulin , adipocytokines , growth factor .</brief_summary>
	<brief_title>Metformin Treatment Premature Pubarche Girls</brief_title>
	<detailed_description />
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Puberty , Precocious</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Girls age 410 pubic hair prior 8 year age 2 . Elevated DHEAS level age normal level 3 . Informed consent parent assent girl 1 . Diagnosis incomplete precocious puberty , peripheral precocious puberty , evidence abnormal pituitary , hypothalamic , adrenal , thyroid , gonadal function premature secretion adrenal androgen . 2 . Chronic illness require treatment may interfere growth development , i.e . chronic steroid use , renal failure , etc . 3 . 21hydroxylase deficiency enzyme deficiency lead phenotype congenital adrenal hyperplasia . 21hydroxylase deficiency exclude patient fast 17hydroxyprogesterone ( 17OHP ) level &lt; 2 ng/mL . In case elevate fast 17OHP level , ACTH stimulation test perform . A 1hour stimulate value &gt; 10 ng/mL exclusion 82 . As 21 hydroxylase deficiency congenital condition , normal level past 17hydroxyprogesterone allows entry study . 4 . Uncorrected thyroid disease ( define TSH &lt; 0.2 mIU/ML &gt; 5.5 mIU/mL ) . A normal level within last year adequate entry . 5 . Type I Type II diabetes ( define fast serum glucose &gt; 125mg/dL two occasion 83 ) , patient receive antidiabetic medication insulin , thiazolidinediones , acarbose , sulfonylurea ; patient currently receive metformin XR diagnosis Type I Type II diabetes PCOS also specifically exclude . 6 . Liver disease define AST ALT &gt; 2 time normal total bilirubin &gt; 2.5 mg/dL . 7 . Renal disease define BUN &gt; 30 mg/dL serum creatinine &gt; 1.4 mg/dL . 8 . Significant anemia ( Hemoglobin &lt; 10 mg/dL ) . 9 . History deep venous thrombosis , pulmonary embolus , cerebrovascular accident . 10 . Known heart disease ( New York Heart Association Class II high ) . 11 . Enrolled simultaneously investigative study require medication , proscribe study medication , otherwise prevent compliance protocol . Patients anticipate take longer one month break protocol enrol . 12 . Concomitant use medication know affect reproductive function metabolism . These medication include growth hormone , IGF1 , medroxyprogesterone acetate , oral contraceptive , GnRH agonists antagonist , antiandrogens , gonadotropin , antiobesity drug , somatostatin , diazoxide , ACE inhibitor , calcium channel blocker . The washout period medication three month . 13 . Suspected adrenal ovarian tumor secrete androgen ectopic steroid secrete tumor . 14 . Suspected Cushing 's syndrome . 15 . Lactose intolerance ( placebo filler lactose ) . 16 . Known hypersensitivity study medication , include ACTH GnRH , excipients . 17 . Any concomitant medical condition opinion investigator , may expose subject unacceptable level safety risk , affect subject compliance . 18 . Subjects anticipate surgery associate restrict intake fluid radiological study contrast dye study period . 19 . Any concomitant medical condition opinion investigator , may expose subject unacceptable level safety risk , affect subject compliance .</criteria>
	<gender>Female</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Puberty</keyword>
	<keyword>Hormones</keyword>
</DOC>